Relmada Therapeutics (RLMD)
Market Price (3/4/2026): $4.655 | Market Cap: $154.5 MilSector: Health Care | Industry: Biotechnology
Relmada Therapeutics (RLMD)
Market Price (3/4/2026): $4.655Market Cap: $154.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Neurological & Psychiatric Health, and Precision Medicine. Themes include Depression & Mood Disorder Therapies, CNS Drug Development, Show more. | Trading close to highsDist 52W High is -3.5% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Weak multi-year price returns2Y Excs Rtn is -55%, 3Y Excs Rtn is -31% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -58 Mil | |
| Stock price has recently run up significantly6M Rtn6 month market price return is 229%, 12M Rtn12 month market price return is 1731% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -41% | ||
| High stock price volatilityVol 12M is 150% | ||
| Key risksRLMD key risks include [1] repeated Phase 3 clinical trial failures of its lead candidate, Show more. |
| Megatrend and thematic driversMegatrends include Neurological & Psychiatric Health, and Precision Medicine. Themes include Depression & Mood Disorder Therapies, CNS Drug Development, Show more. |
| Trading close to highsDist 52W High is -3.5% |
| Weak multi-year price returns2Y Excs Rtn is -55%, 3Y Excs Rtn is -31% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -58 Mil |
| Stock price has recently run up significantly6M Rtn6 month market price return is 229%, 12M Rtn12 month market price return is 1731% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -41% |
| High stock price volatilityVol 12M is 150% |
| Key risksRLMD key risks include [1] repeated Phase 3 clinical trial failures of its lead candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Relmada Therapeutics (RLMD) stock has gained about 5% since 11/30/2025 because of the following key factors:
1. Positive Analyst Coverage and Price Target Increases.
Multiple analyst firms initiated or upgraded coverage of Relmada Therapeutics, Inc. (RLMD) with significantly raised price targets, indicating a positive outlook for the company. On March 2, 2026, Lucid Capital Markets initiated coverage with a 'Buy' rating and a price target of USD 14.00. This followed Leerink Partners' upgrade on January 23, 2026, from 'Market Perform' to 'Outperform' with an USD 8.00 price target, and Jefferies' initiation on December 22, 2025, with a 'Buy' rating and a USD 9.00 price target. Notably, on November 19, 2025, Mizuho upgraded RLMD from 'Neutral' to 'Outperform' and increased its price target from USD 1.00 to USD 10.00, representing a 900% change. The consensus among analysts resulted in an average target price of approximately USD 9.00 to USD 9.86, accompanied by "Strong Buy" or "Buy" recommendations.
2. Advancement and FDA Alignment for NDV-01 in Non-Muscle Invasive Bladder Cancer (NMIBC).
Relmada Therapeutics made significant progress and received positive regulatory feedback for its lead clinical program, NDV-01, for the treatment of NMIBC. On January 12, 2026, the company announced that it had received written feedback from the FDA, confirming alignment on registrational study designs for NDV-01 in two distinct NMIBC indications. The FDA supported a single-arm, open-label registrational trial for high-grade BCG-unresponsive NMIBC with carcinoma in situ (CIS) and a single randomized-to-observation trial for intermediate-risk NMIBC. These pivotal Phase 3 trials are anticipated to commence in the first half of 2026. This regulatory progress built upon earlier positive data from the Q3 2025 earnings report on November 13, 2025, which highlighted a 92% "anytime" complete response rate for NDV-01 among 25 evaluable patients in Phase 2.
Show more
1. Positive Analyst Coverage and Price Target Increases.
Multiple analyst firms initiated or upgraded coverage of Relmada Therapeutics, Inc. (RLMD) with significantly raised price targets, indicating a positive outlook for the company. On March 2, 2026, Lucid Capital Markets initiated coverage with a 'Buy' rating and a price target of USD 14.00. This followed Leerink Partners' upgrade on January 23, 2026, from 'Market Perform' to 'Outperform' with an USD 8.00 price target, and Jefferies' initiation on December 22, 2025, with a 'Buy' rating and a USD 9.00 price target. Notably, on November 19, 2025, Mizuho upgraded RLMD from 'Neutral' to 'Outperform' and increased its price target from USD 1.00 to USD 10.00, representing a 900% change. The consensus among analysts resulted in an average target price of approximately USD 9.00 to USD 9.86, accompanied by "Strong Buy" or "Buy" recommendations.
2. Advancement and FDA Alignment for NDV-01 in Non-Muscle Invasive Bladder Cancer (NMIBC).
Relmada Therapeutics made significant progress and received positive regulatory feedback for its lead clinical program, NDV-01, for the treatment of NMIBC. On January 12, 2026, the company announced that it had received written feedback from the FDA, confirming alignment on registrational study designs for NDV-01 in two distinct NMIBC indications. The FDA supported a single-arm, open-label registrational trial for high-grade BCG-unresponsive NMIBC with carcinoma in situ (CIS) and a single randomized-to-observation trial for intermediate-risk NMIBC. These pivotal Phase 3 trials are anticipated to commence in the first half of 2026. This regulatory progress built upon earlier positive data from the Q3 2025 earnings report on November 13, 2025, which highlighted a 92% "anytime" complete response rate for NDV-01 among 25 evaluable patients in Phase 2.
Show more
Stock Movement Drivers
Fundamental Drivers
The 3.5% change in RLMD stock from 11/30/2025 to 3/3/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 11302025 | 3032026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.51 | 4.67 | 3.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 33 | 33 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 3/3/2026| Return | Correlation | |
|---|---|---|
| RLMD | 3.5% | |
| Market (SPY) | -0.4% | 26.3% |
| Sector (XLV) | -0.6% | -0.7% |
Fundamental Drivers
The 317.0% change in RLMD stock from 8/31/2025 to 3/3/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 8312025 | 3032026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.12 | 4.67 | 317.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 33 | 33 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 3/3/2026| Return | Correlation | |
|---|---|---|
| RLMD | 317.0% | |
| Market (SPY) | 5.8% | 14.8% |
| Sector (XLV) | 14.6% | 11.6% |
Fundamental Drivers
The 1696.2% change in RLMD stock from 2/28/2025 to 3/3/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282025 | 3032026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.26 | 4.67 | 1696.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 30 | 33 | -9.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2025 to 3/3/2026| Return | Correlation | |
|---|---|---|
| RLMD | 1696.2% | |
| Market (SPY) | 15.5% | 11.2% |
| Sector (XLV) | 6.6% | 8.2% |
Fundamental Drivers
The 29.7% change in RLMD stock from 2/28/2023 to 3/3/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282023 | 3032026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.60 | 4.67 | 29.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 30 | 33 | -9.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2023 to 3/3/2026| Return | Correlation | |
|---|---|---|
| RLMD | 29.7% | |
| Market (SPY) | 78.1% | 9.0% |
| Sector (XLV) | 29.0% | 8.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RLMD Return | -30% | -85% | 19% | -87% | 829% | 0% | -85% |
| Peers Return | -26% | -13% | -15% | -50% | -32% | 2% | -81% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 83% |
Monthly Win Rates [3] | |||||||
| RLMD Win Rate | 50% | 50% | 50% | 33% | 75% | 67% | |
| Peers Win Rate | 33% | 58% | 54% | 38% | 56% | 33% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 67% | |
Max Drawdowns [4] | |||||||
| RLMD Max Drawdown | -47% | -90% | -36% | -91% | -52% | -27% | |
| Peers Max Drawdown | -37% | -32% | -42% | -51% | -49% | -7% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, AKTS, ALPS, DCOY, DFTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/3/2026 (YTD)
How Low Can It Go
| Event | RLMD | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -94.5% | -25.4% |
| % Gain to Breakeven | 1710.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -52.6% | -33.9% |
| % Gain to Breakeven | 110.8% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -37.5% | -19.8% |
| % Gain to Breakeven | 60.1% | 24.7% |
| Time to Breakeven | 49 days | 120 days |
Compare to VRTX, AKTS, ALPS, DCOY, DFTX
In The Past
Relmada Therapeutics's stock fell -94.5% during the 2022 Inflation Shock from a high on 1/12/2021. A -94.5% loss requires a 1710.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Relmada Therapeutics (RLMD)
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
AI Analysis | Feedback
Here are 1-3 brief analogies for Relmada Therapeutics (RLMD):
- Relmada Therapeutics is a clinical-stage biotech company with its future largely depending on one promising drug for depression, similar to how Moderna was before its vaccine breakthrough.
- Relmada Therapeutics is a small biotech aiming to be a leader in CNS disorders, similar to a nascent Biogen (known for neurology drugs) but with its current focus entirely on one depression treatment.
- Relmada Therapeutics is a speculative biotech company where its future rests on one breakthrough drug for depression, much like an early-stage Vertex Pharmaceuticals betting its future on its cystic fibrosis treatments.
AI Analysis | Feedback
```html- REL-1017 (esmethadone): An investigational NMDA receptor modulator being developed as an adjunctive treatment for major depressive disorder (MDD).
AI Analysis | Feedback
Relmada Therapeutics (RLMD) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for central nervous system (CNS) disorders. As of the current date, the company does not have any commercialized products available for sale on the market. Therefore, Relmada Therapeutics does not have "major customers" in the traditional sense of companies or individuals purchasing its products. Its primary activities are research and development, including conducting clinical trials for its lead product candidate, REL-1017, for the treatment of Major Depressive Disorder (MDD). The company's funding primarily comes from financing activities, such as equity offerings and potential strategic partnerships or licensing agreements with larger pharmaceutical companies, rather than from product sales. If Relmada Therapeutics were to successfully commercialize a product in the future, its customers would primarily be:- Pharmaceutical Wholesalers/Distributors: Companies like McKesson (MCK), AmerisourceBergen (ABC), and Cardinal Health (CAH) would purchase the product for distribution to pharmacies and healthcare providers.
- Hospitals and Healthcare Systems: Major healthcare networks and hospitals would purchase the drug for use within their facilities.
- Retail and Specialty Pharmacies: Pharmacies would stock and dispense the medication to patients based on prescriptions.
AI Analysis | Feedback
nullAI Analysis | Feedback
Sergio Traversa, Pharm.D., MBA, Chief Executive Officer
Dr. Traversa has served as Relmada Therapeutics' Chief Executive Officer since April 2012. He was the co-founder and CEO of Medeor Inc., a pharmaceutical company spun off from Cornell University. He also was a founding partner of Ardana Capital, a pharmaceutical and biotechnology investment advisory firm. Dr. Traversa has over 25 years of experience in the healthcare sector, including management positions in the pharmaceutical industry and roles in investing and strategic advisory. He held financial analyst, portfolio management, and strategic advisory positions at U.S. investment firms such as Mehta and Isaly, Mehta Partners, ING Barings, Merlin BioMed, and Rx Capital. Previously, he was the Area Manager for Southern Europe of Therakos Inc., a cancer and immunology division of Johnson & Johnson. Before that, Dr. Traversa worked at Eli Lilly as Marketing Manager of the Hospital Business Unit and was part of the CNS team involved in the launch of Prozac and the early development of Zyprexa and Cymbalta. He began his career as a sales representative at Farmitalia Carlo Erba, which was later acquired by Pharmacia and is now part of Pfizer. Dr. Traversa also served as interim CEO and CFO of Actinium Pharmaceuticals, Inc. and is currently a board member of Actinium.
Maged Shenouda, Chief Financial Officer
Mr. Shenouda previously served as CFO and Executive Vice President of Corporate Development for AzurRx BioPharma, Inc.
Charles S. Ence, Chief Accounting and Compliance Officer
Charles Ence currently serves as Relmada Therapeutics' Chief Accounting and Compliance Officer.
Raj S. Pruthi, MD, Chief Medical Officer
Dr. Pruthi is an accomplished physician, surgeon, and clinical scientist with extensive experience in academic medicine and industry. Prior to joining Relmada, Dr. Pruthi was Chief Medical Officer at enGene Holdings Inc., where he led a global team in the development of a registrational therapeutic trial for bladder cancer. He also served as the Global Medical Affairs Leader, Bladder Cancer and Senior Medical Director, Oncology (Global – Prostate and Bladder Cancer) at Johnson and Johnson Innovative Medicine.
Paolo Manfredi, Chief Scientific Officer
Paolo Manfredi is the Chief Scientific Officer at Relmada Therapeutics.
AI Analysis | Feedback
Key Business Risks for Relmada Therapeutics (RLMD)
Relmada Therapeutics, Inc. (RLMD) faces several significant risks inherent to the biotechnology sector, particularly related to clinical trial outcomes, financial stability, and regulatory hurdles.
- Clinical Trial Failures and Pipeline Risk: The most prominent risk to Relmada Therapeutics is the high rate of failure in its clinical development programs. The company recently discontinued two Phase 3 trials (Reliance II and Relight) for its lead candidate, REL-1017, intended for major depressive disorder, after interim analyses indicated they were unlikely to achieve their primary efficacy endpoints. This follows a previous failure of REL-1017 in the Phase 3 RELIANCE III study. These repeated setbacks led to a substantial decline in the company's stock value and prompted Relmada to explore strategic alternatives, including a potential sale or merger. While the company is advancing other candidates like NDV-01 for non-muscle invasive bladder cancer into Phase 3, the inherent risk of clinical trial failure remains a critical concern for its remaining pipeline.
- Financial Instability and Funding Risk: Relmada Therapeutics has consistently operated at a loss, reporting a net loss of $21.8 million in Q1 2024 and an operating loss of approximately $98.54 million over the preceding twelve months. Analysts do not anticipate the company achieving profitability in the current year. The extensive costs associated with conducting late-stage clinical trials, especially for planned Phase 3 studies of NDV-01, necessitate substantial capital. Despite holding some cash and investments, concerns exist about the sufficiency of its cash runway, with estimates suggesting a limited timeframe based on current burn rates. This financial position indicates a high probability of future capital raises, which could lead to further dilution of shareholder value. The discontinuation of the REL-1017 trials further diminishes near-term revenue potential and compounds financial uncertainty.
- Regulatory Risk and Dependence on FDA Approvals: As a clinical-stage biotechnology company, Relmada's ability to bring its drug candidates to market is contingent upon navigating complex regulatory pathways and securing approvals from health authorities like the U.S. Food and Drug Administration (FDA). While the company has received positive feedback from the FDA regarding potential registrational pathways for NDV-01, ongoing and future interactions with regulatory bodies are subject to inherent uncertainties. Any delays in gaining regulatory alignment, or failure to meet FDA requirements for efficacy and safety, could significantly impact development timelines, increase costs, and jeopardize the commercial viability of its product candidates.
AI Analysis | Feedback
The emerging threat to Relmada Therapeutics stems from the rapid advancement and potential market entry of psychedelic-assisted therapies for Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).
Companies like Compass Pathways, among others, are in late-stage clinical trials (e.g., Phase 3 for psilocybin in TRD) and have received regulatory designations such as FDA Breakthrough Therapy. These therapies offer a fundamentally different treatment paradigm compared to Relmada's lead candidate, REL-1017, which is a daily oral medication. Psychedelic-assisted therapies have demonstrated the potential for rapid, profound, and durable antidepressant effects after only a limited number of administrations (e.g., one or two doses), which could significantly reduce or eliminate the need for chronic daily medication over extended periods.
If these single or limited-dose therapies are approved and gain market acceptance, they could disrupt the market for daily oral antidepressants by shifting patient and prescriber preferences towards therapies offering long-term efficacy without the burden of continuous daily dosing. This represents a clear emerging threat that could fundamentally alter the competitive landscape for psychiatric treatments, similar to how streaming services disrupted physical media rentals.
AI Analysis | Feedback
Relmada Therapeutics, Inc. (RLMD) is a clinical-stage biotechnology company with a pipeline of product candidates targeting various central nervous system disorders and oncology. The addressable markets for their main products or services are as follows: * NDV-01 (for high-grade Non-Muscle Invasive Bladder Cancer - NMIBC): The U.S. NMIBC market is estimated to be a multi-billion dollar opportunity. Annually, 600,000 patients in the U.S. are affected by NMIBC. Global numbers for this market are projected to be higher due to increasing incidence of bladder cancer. * Sepranolone (for Tourette syndrome and Prader-Willi syndrome - PWS): For Tourette syndrome, the U.S. prevalence is approximately 350,000 patients. In the U.S., there are 20,000 patients with PWS. The global prevalence for PWS ranges from 350,000 to 400,000 patients. The company's prior lead product candidate, REL-1017, for Major Depressive Disorder (MDD), has had its Phase 3 trials discontinued due to futility.AI Analysis | Feedback
Relmada Therapeutics (RLMD) faces a significant shift in its prospective revenue drivers following the discontinuation of its lead Major Depressive Disorder (MDD) drug, REL-1017, from Phase 3 trials due to a futility assessment. This has prompted the company to explore strategic alternatives, including potential sale of assets, merger, or acquisition of new products. Consequently, future revenue growth will hinge on the successful development and potential commercialization of its remaining pipeline and any outcomes from its strategic review. Here are 3-5 expected drivers of future revenue growth for Relmada Therapeutics over the next 2-3 years, contingent on successful clinical development and strategic execution:- Advancement and Potential Commercialization of REL-P11 for Metabolic Diseases: Relmada is progressing with REL-P11, a proprietary low-dose, modified-release psilocybin formulation. Following the completion of a Phase 1 safety study, the company plans to initiate a Phase 2 study in the first half of 2025 for metabolic diseases. Positive results from this Phase 2 trial and subsequent successful clinical development could lead to its eventual commercialization, representing a new product line and significant revenue potential.
- Development and Commercialization of NDV-01 for Non-Muscle Invasive Bladder Cancer (NMIBC): The company is advancing NDV-01, a controlled-release intravesical formulation, which is currently in a Phase 2 clinical trial for aggressive forms of NMIBC. Success in ongoing and future clinical trials for NDV-01, leading to regulatory approval and market entry, would create a new revenue stream in the oncology space.
- Progression of Sepranolone for Neurological and Neuropsychiatric Disorders: Sepranolone, a neurosteroid epimer, is Phase 2b-ready for potential indications such as Prader-Willi Syndrome, Tourette Syndrome, and excessive tremor. Successful progression through clinical development and eventual commercialization of sepranolone would diversify Relmada's product portfolio and open new market opportunities.
- Strategic Transactions and Acquisition of New Assets: With the discontinuation of REL-1017, Relmada is actively exploring strategic alternatives to maximize shareholder value, including mergers, reverse mergers, or the acquisition of assets or development rights for other products. Should Relmada successfully acquire or license promising new product candidates, these could become significant drivers of future revenue growth within the 2-3 year timeframe, depending on their stage of development.
AI Analysis | Feedback
Share Issuance
- In November 2025, Relmada Therapeutics priced an underwritten offering of 40,142,000 shares of common stock and pre-funded warrants to purchase up to 5,315,000 shares, expecting to raise approximately $100 million in gross proceeds.
- The common stock was offered at $2.20 per share, and pre-funded warrants at $2.199 per pre-funded warrant.
- Net proceeds from this offering are intended to fund working capital, clinical studies, systems, and potential strategic investments.
Outbound Investments
- In early 2025, Relmada Therapeutics strategically acquired development rights to two new product candidates: NDV-01, for non-muscle invasive bladder cancer, and sepranolone, for compulsion-related disorders.
- As of February 2025, Relmada Therapeutics completed a Corporate Asset Purchase with Asarina Pharma for Tourette Syndrome Therapy Compound Rights.
- In July 2021, the company acquired development and commercial rights to a novel psilocybin and derivate program from Arbormentis LLC for all ex-Asia territories, including the U.S. and Europe.
Capital Expenditures
- Relmada Therapeutics' free cash flow, which is operating cash flow minus capital expenditures, was -$0.052 billion in 2024 and -$0.052 billion in 2023.
- The company's free cash flow was -$0.104 billion in 2022 and -$0.092 billion in 2021.
Trade Ideas
Select ideas related to RLMD.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 11.18 |
| Mkt Cap | 60.2 |
| Rev LTM | 0 |
| Op Inc LTM | -32 |
| FCF LTM | -22 |
| FCF 3Y Avg | -34 |
| CFO LTM | -22 |
| CFO 3Y Avg | -34 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.9% |
| Rev Chg 3Y Avg | 10.4% |
| Rev Chg Q | 9.5% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Mgn LTM | 37.9% |
| Op Mgn 3Y Avg | 24.7% |
| QoQ Delta Op Mgn LTM | 38.7% |
| CFO/Rev LTM | 30.3% |
| CFO/Rev 3Y Avg | 20.5% |
| FCF/Rev LTM | 26.6% |
| FCF/Rev 3Y Avg | 17.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 60.2 |
| P/S | 10.0 |
| P/EBIT | 11.6 |
| P/E | 13.8 |
| P/CFO | 14.6 |
| Total Yield | -16.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -70.2% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.4% |
| 3M Rtn | 9.5% |
| 6M Rtn | 17.5% |
| 12M Rtn | 7.8% |
| 3Y Rtn | 24.4% |
| 1M Excs Rtn | 2.2% |
| 3M Excs Rtn | 4.0% |
| 6M Excs Rtn | 12.0% |
| 12M Excs Rtn | -6.3% |
| 3Y Excs Rtn | -42.6% |
Price Behavior
Price Behavior
| Market Price | $4.67 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 03/16/2018 | |
| Distance from 52W High | -3.5% | |
| 50 Days | 200 Days | |
| DMA Price | $4.14 | $2.31 |
| DMA Trend | up | indeterminate |
| Distance from DMA | 12.7% | 101.7% |
| 3M | 1YR | |
| Volatility | 77.0% | 150.9% |
| Downside Capture | 154.21 | -62.73 |
| Upside Capture | 251.36 | 247.05 |
| Correlation (SPY) | 25.1% | 11.3% |
RLMD Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.74 | 1.11 | 1.89 | 0.96 | 0.83 | 0.72 |
| Up Beta | 4.47 | 4.93 | 5.62 | 2.14 | 1.05 | 0.84 |
| Down Beta | 0.54 | -1.16 | 0.46 | -0.69 | 0.40 | 0.28 |
| Up Capture | 672% | 117% | 158% | 568% | 504% | 37% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 8 | 16 | 25 | 59 | 124 | 348 |
| Down Capture | 257% | 92% | 143% | -53% | -127% | 90% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 13 | 25 | 35 | 62 | 123 | 376 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RLMD | |
|---|---|---|---|---|
| RLMD | 1,689.7% | 151.0% | 2.58 | - |
| Sector ETF (XLV) | 6.7% | 17.4% | 0.22 | 8.2% |
| Equity (SPY) | 15.6% | 19.3% | 0.63 | 11.2% |
| Gold (GLD) | 79.3% | 26.1% | 2.22 | -1.1% |
| Commodities (DBC) | 17.8% | 17.1% | 0.80 | 4.6% |
| Real Estate (VNQ) | 5.6% | 16.6% | 0.16 | 1.6% |
| Bitcoin (BTCUSD) | -18.7% | 45.2% | -0.32 | 2.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RLMD | |
|---|---|---|---|---|
| RLMD | -33.1% | 112.4% | 0.32 | - |
| Sector ETF (XLV) | 8.1% | 14.5% | 0.37 | 6.9% |
| Equity (SPY) | 13.2% | 17.0% | 0.61 | 9.6% |
| Gold (GLD) | 22.8% | 17.3% | 1.08 | 0.4% |
| Commodities (DBC) | 10.8% | 19.0% | 0.46 | 1.6% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 8.8% |
| Bitcoin (BTCUSD) | 6.7% | 56.8% | 0.34 | 2.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RLMD | |
|---|---|---|---|---|
| RLMD | 8.9% | 163.6% | 0.66 | - |
| Sector ETF (XLV) | 10.8% | 16.5% | 0.54 | 10.3% |
| Equity (SPY) | 15.3% | 17.9% | 0.74 | 10.3% |
| Gold (GLD) | 14.9% | 15.6% | 0.80 | -1.9% |
| Commodities (DBC) | 9.1% | 17.6% | 0.43 | 2.2% |
| Real Estate (VNQ) | 6.5% | 20.7% | 0.28 | 9.4% |
| Bitcoin (BTCUSD) | 66.5% | 66.8% | 1.06 | 3.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/13/2025 | 1.8% | 11.3% | 16.0% |
| 8/7/2025 | -2.4% | 0.9% | 165.8% |
| 3/27/2025 | -0.4% | -7.4% | 19.8% |
| 3/19/2024 | -17.4% | -12.7% | -19.9% |
| 11/8/2023 | -0.3% | 1.0% | -14.7% |
| 8/8/2023 | 7.1% | 34.3% | 39.8% |
| 3/23/2023 | -2.2% | -3.4% | 8.2% |
| 11/10/2022 | 8.7% | 2.7% | -42.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 4 | 7 | 7 |
| # Negative | 6 | 3 | 3 |
| Median Positive | 7.3% | 2.7% | 16.0% |
| Median Negative | -2.3% | -7.4% | -19.9% |
| Max Positive | 8.7% | 34.3% | 165.8% |
| Max Negative | -17.4% | -12.7% | -42.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/19/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/23/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 03/25/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Traversa, Sergio | Chief Executive Officer | Direct | Buy | 12162025 | 4.12 | 27,500 | 113,300 | 5,356,000 | Form |
| 2 | Shenouda, Maged | Chief Financial Officer | Direct | Buy | 12162025 | 4.12 | 11,665 | 48,060 | 3,296,000 | Form |
| 3 | Shenouda, Maged | Chief Financial Officer | Direct | Buy | 11062025 | 2.20 | 500,000 | 1,100,000 | 1,734,337 | Form |
| 4 | Ence, Chuck | CAO and COO | Direct | Buy | 11062025 | 2.20 | 136,000 | 299,200 | 888,648 | Form |
| 5 | Traversa, Sergio | Chief Executive Officer | Direct | Buy | 11062025 | 2.20 | 272,500 | 599,500 | 2,799,500 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.